Reprocell U.s.a., Inc.

Reprocell U.s.a., Inc., a minority-owned, Asian-Pacific American-owned for-profit corporation based in Beltsville, Maryland, supplies biological research materials and laboratory testing services to federal health and life-sciences agencies as a prime contractor on small-dollar purchase orders. The vendor operates exclusively as a prime across its federal footprint (100% of awards); it does not pursue subcontracting work. Reprocell competes entirely in full-and-open procurements with no set-aside designations, selling clinical-grade biological materials (cell lines, tissue cultures), RNA and DNA extraction and processing services, and related laboratory support to biomedical research programs.

Customer concentration sits heavily with the National Institutes of Health and its subordinate institutes. The top five customer agencies account for 50% of awards by count and 54% of combined potential value, led by NIH across the National Institute of Environmental Health Sciences (9 awards, $187 thousand), the National Heart Lung and Blood Institute (4 awards, $181 thousand), and the National Human Genome Research Institute (7 awards, $136 thousand). The broader HHS National Institutes of Health organization (parent agency accounting) carries 20 awards and $280 thousand in combined potential value. Non-HHS customers include the Department of Veterans Affairs Veterans Health Administration and the National Institute on Aging. Recent representative purchase orders include a $32,266 supply of 124 PAXgene tubes to the National Institute on Alcohol Abuse and Alcoholism (July 2026), a $32,048 RNA extraction and processing service from biological samples (June 2026), and a $20,903 laboratory testing service for RNA and DNA extraction from the National Institute on Aging (June 2024). Reprocell places task orders under the Blanket Purchase Agreement HHSN263200000053455B (19 task orders, $91 thousand combined potential value).

Award activity is sparse. The vendor shows one award in 2021, one in 2022, one in 2023, two in 2024, and two in 2026, reflecting minimal federal footprint growth. Combined potential value across all 98 awards totals $1.5 million; combined dollars obligated reach $6.5 million, indicating frequent task-order replenishment and recompete within existing blanket purchase agreements. Two awards (combined potential value $64 thousand) complete within the next twenty-four months. The vendor's primary NAICS categories are All Other Health and Personal Care Stores (22 awards) and Research and Development in Biotechnology (16 awards), with dominant PSC codes in Reference Laboratory Testing (21 awards) and Drugs And Biologicals (19 awards). SCI-reported service-contract activity shows minimal federal services capture — one record in FY2022 representing 1.3 FTEs as a named subcontractor on a higher-value prime service contract, indicating that Reprocell's federal presence is dominated by goods procurement (laboratory supplies, materials, extraction services) below the SCI $150,000 threshold rather than reportable service contracts.